These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35325149)

  • 1. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
    Gadelha M; Bex M; Feelders RA; Heaney AP; Auchus RJ; Gilis-Januszewska A; Witek P; Belaya Z; Yu Y; Liao Z; Ku CHC; Carvalho D; Roughton M; Wojna J; Pedroncelli AM; Snyder PJ
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2882-e2895. PubMed ID: 35325149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
    Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
    Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
    Fleseriu M; Newell-Price J; Pivonello R; Shimatsu A; Auchus RJ; Scaroni C; Belaya Z; Feelders RA; Vila G; Houde G; Walia R; Izquierdo M; Roughton M; Pedroncelli AM; Biller BMK
    Eur J Endocrinol; 2022 Oct; 187(4):531-541. PubMed ID: 35980235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
    Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
    Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
    Pivonello R; Fleseriu M; Newell-Price J; Shimatsu A; Feelders RA; Kadioglu P; Tabarin A; Brue TC; Geer EB; Piacentini A; Pedroncelli AM; Biller BMK
    J Endocrinol Invest; 2024 Oct; 47(10):2437-2448. PubMed ID: 38696122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
    Dormoy A; Haissaguerre M; Vitellius G; Do Cao C; Geslot A; Drui D; Lasolle H; Vieira-Pinto O; Salenave S; François M; Puerto M; Boullay HD; Mayer A; Rod A; Laurent C; Chanson P; Reznik Y; Castinetti F; Chabre O; Baudin E; Raverot G; Tabarin A; Young J
    J Clin Endocrinol Metab; 2023 May; 108(6):1475-1487. PubMed ID: 36470583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
    Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
    Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.
    Yuen KCJ
    Endocr Pract; 2021 Sep; 27(9):956-965. PubMed ID: 34389514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
    Feelders RA; Fleseriu M; Kadioglu P; Bex M; González-Devia D; Boguszewski CL; Yavuz DG; Patino H; Pedroncelli AM; Maamari R; Chattopadhyay A; Biller BMK; Pivonello R
    Front Endocrinol (Lausanne); 2023; 14():1165681. PubMed ID: 37876540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osilodrostat for Cushing Disease and Its Role in Pediatrics.
    Groselj U; Sikonja J; Battelino T
    Horm Res Paediatr; 2023; 96(6):573-580. PubMed ID: 35045421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
    Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
    Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
    Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
    Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osilodrostat for the treatment of Cushing's disease.
    Rasool S; Skinner BW
    Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.